PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
33 hedge funds and large institutions have $27.5M invested in PLx Pharma Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
14% more funds holding
Funds holding: 29 → 33 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $36.1M → $27.5M (-$8.56M)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$950K |
| 2 |
Goldman Sachs
New York
|
+$887K |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
+$174K |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$135K |
| 5 |
SCA
Stonebridge Capital Advisors
St Paul,
Minnesota
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$3.41M |
| 2 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$410K |
| 3 |
OPPM
Opus Point Partners Management
New York
|
-$280K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$252K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$159K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $6K | +$5.53K | +87 | New |
|
27
UBS Group
Zurich,
Switzerland
| $5K | -$13.6K | -214 | -77% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $3K | -$11.6K | -183 | -81% |
|
|
ASN
29
Advisory Services Network
Atlanta,
Georgia
| $3K | +$2.42K | +38 | New |
|
|
FANJ
30
Financial Architects (New Jersey)
Marlton,
New Jersey
| $3K | +$2.8K | +44 | New |
|
31
Bank of America
Charlotte,
North Carolina
| $1K | +$445 | +7 | New |
|
32
Geode Capital Management
Boston,
Massachusetts
| $315 | +$21.9K | +345 | +9% |
|
|
OPPM
33
Opus Point Partners Management
New York
| – | -$280K | -3,125 | Closed |
|
|
34
Alyeska Investment Group
Chicago,
Illinois
| – | -$252K | -2,813 | Closed |
|
|
BFM
35
Boothbay Fund Management
New York
| – | -$159K | -1,775 | Closed |
|
36
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$109K | -1,224 | Closed |
|
37
Citigroup
New York
| – | +$381 | +6 | New |
|
PLXP Hedge Fund Activity: Q1 2016 in Review
33 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2016, worth a combined $27.5M — down 24% from $36.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PLXP positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 12 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $950K. The largest seller was Tourbillon Capital Partners, cutting an estimated $3.41M.
- 33 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2016, up from 29 in Q4 2015.
- Funds reported $27.5M of PLx Pharma Inc. Common Stock stock for Q1 2016, down 24% quarter-over-quarter.
- 8 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2016 and 4 closed out, a net change of +4 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q1 2016 was 683 Capital Management, an estimated $950K added.
- The largest PLx Pharma Inc. Common Stock seller in Q1 2016 was Tourbillon Capital Partners, an estimated $3.41M sold.
Based on aggregated 13F filings for Q1 2016.